Newsfeed : GSK and Pfizer Launch HIV-Specific Drug Company

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Newsfeed » November 2009

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

November 3, 2009

GSK and Pfizer Launch HIV-Specific Drug Company

GlaxoSmithKline and Pfizer announced November 3 the launch of ViiV Healthcare, a collaboration between both pharmaceutical companies’ HIV drug divisions. The new company, based in London and the United States, aims to address needs specific to those living with HIV worldwide through investing in innovative research and by offering improved patient access to treatment.

Dominique Limet, MD, chief executive officer of ViiV Healthcare, said that while antiretroviral treatment advances have transformed HIV from a life-threatening disease to a chronic illness, further research is needed to improve the life expectancy—and quality of life—for those living with the virus.

Presently, on average, HIV-positive people live 10 fewer years than their HIV-negative peers. “This is unacceptable, and we must stay relentless in the pursuit of new medicines,” Limet said.

ViiV Healthcare currently has 10 HIV therapies and seven medicines in the pipeline, including five compounds in Phase II development. A total of 17 molecules in the company’s portfolio could be developed into new HIV drug treatments.

“ViiV Healthcare’s [research and development] will not solely focus on creating ‘new’ medicines,” Limet said. “We will explore the potential of all our molecules for broader utility—for example to create new formulations and combinations that can help improve adherence or overcome resistance to the virus.”

Limet also stated that ViiV intends to have several members of the HIV community on its board. The methods by which ViiV will solicit nominations will be revealed at a later date.

Search: GlaxoSmithKline, GSK, Pfizer, pharmaceutical, United States, London, pipeline, life expectancy, Dominique Limet, ViiV


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    oceanblue65
    louisiana
    Louisiana


    TaintedloveDC
    Washington
    DC


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.